buthionine sulfoximine has been researched along with Parkinson Disease in 18 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (22.22) | 18.2507 |
| 2000's | 11 (61.11) | 29.6817 |
| 2010's | 3 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gunjima, K; Hashida, K; Hori, O; Konishi, T; Matsugo, S; Nakamura, Y; Takakura, K; Tomiyama, R; Yamada, T | 1 |
| Andersen, JK; Chinta, SJ; Rajagopalan, S | 1 |
| Davey, GP; Heales, SJ; Menzes, A | 1 |
| Cheong, J; JnoBaptiste, R; Kramer, BC; Mytilineou, C; Olanow, CW; Robakis, T; Yabut, JA | 1 |
| Chen, CF; Ho, LT; Lin, AM | 1 |
| Ames, BN; Andersen, JK; Bharat, S; Cochran, BC; Hsu, M; Liu, J | 1 |
| Ehrhart, J; Zeevalk, GD | 1 |
| Esparza, A; Gallardo, V; Muñoz, P; Núñez, MT; Salazar, J; Speisky, H; Tapia, V | 1 |
| Andersen, JK; Chinta, SJ | 1 |
| Bharath, MM; Jagatha, B; Mythri, RB; Vali, S | 1 |
| Drukarch, B; Jongenelen, CA; Langeveld, CH; Schepens, E; Stoof, JC | 1 |
| Jenner, P; Kunikowska, GM; Marsden, CD; Toffa, S; Zeng, BY | 1 |
| Ceballos-Picot, I; Merad-Boudia, M; Nicole, A; Saillé, C; Santiard-Baron, D | 1 |
| Jenner, P; McNaught, KS | 1 |
| Kang, UJ; Kowlessur, D; Lei, XG; Milstien, S; Nakamura, K; Wiatr, T; Wright, DA | 1 |
| Choi, HY; Park, DK; Ross, GM; Song, JH | 1 |
| Canals, S; Casarejos, MJ; de Bernardo, S; Mena, MA; Rodríguez-Martín, E | 1 |
| Gramsbergen, JB; Kornblit, B; Møller Dall, A; Sandberg, M; Zimmer, J | 1 |
18 other study(ies) available for buthionine sulfoximine and Parkinson Disease
| Article | Year |
|---|---|
3,4-dihydroxybenzalacetone protects against Parkinson's disease-related neurotoxin 6-OHDA through Akt/Nrf2/glutathione pathway.
Topics: Buthionine Sulfoximine; Caffeic Acids; Cell Line, Tumor; Dose-Response Relationship, Drug; Glutathione; Humans; Neuroblastoma; Neuroprotective Agents; Neurotoxins; NF-E2-Related Factor 2; Oxidative Stress; Oxidopamine; Parkinson Disease; Protein Transport; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species | 2014 |
Pharmacological prolyl hydroxylase domain inhibition as a therapeutic target for Parkinson's disease.
Topics: Age Factors; Analysis of Variance; Animals; Buthionine Sulfoximine; Cell Line, Transformed; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Glutathione; Hydroxybenzoates; Mass Spectrometry; Mice; Mice, Transgenic; Mitochondria; Oxygen Consumption; Parkinson Disease; Prolyl Hydroxylases; Prolyl-Hydroxylase Inhibitors; Rats; Substantia Nigra | 2014 |
Depletion of glutathione does not affect electron transport chain complex activity in brain mitochondria: Implications for Parkinson disease and postmortem studies.
Topics: Animals; Animals, Suckling; Brain; Buthionine Sulfoximine; Cells, Cultured; Electron Transport; Electron Transport Complex I; Enzyme Inhibitors; Glutamate-Cysteine Ligase; Glutathione; Humans; Male; Mitochondria; Oxidation-Reduction; Parkinson Disease; Postmortem Changes; Rats; Rats, Wistar | 2011 |
Lipopolysaccharide prevents cell death caused by glutathione depletion: possible mechanisms of protection.
Topics: Animals; Arachidonic Acid; Astrocytes; Brain; Buthionine Sulfoximine; Cell Death; Cells, Cultured; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Fetus; Free Radical Scavengers; Glutathione; Interleukin-1; Lipopolysaccharides; Microglia; Neuroglia; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Pregnancy; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Superoxides; Up-Regulation | 2002 |
Neuroprotective effect of intermittent hypoxia on iron-induced oxidative injury in rat brain.
Topics: Animals; Atmosphere Exposure Chambers; Brain; Buthionine Sulfoximine; Catalase; Disease Models, Animal; Drug Administration Routes; Female; Glutathione; Glutathione Disulfide; Glutathione Peroxidase; Hypoxia; Iron; Parkinson Disease; Parkinson Disease, Secondary; Rats; Rats, Wistar; Substantia Nigra; Superoxide Dismutase | 2002 |
Pre-treatment with R-lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy.
Topics: Animals; Antioxidants; Buthionine Sulfoximine; Cytoplasm; Glutamate-Cysteine Ligase; Glutathione; Mitochondria; Parkinson Disease; PC12 Cells; Rats; Thioctic Acid | 2002 |
Cooperative interaction between ascorbate and glutathione during mitochondrial impairment in mesencephalic cultures.
Topics: Animals; Antioxidants; Ascorbic Acid; Buthionine Sulfoximine; Chromans; Disulfides; Fluorescent Dyes; Glutathione; Glutathione Disulfide; Malonates; Mesencephalon; Mitochondria; Oxidative Stress; Parkinson Disease; Rats; Rats, Sprague-Dawley | 2003 |
Progressive iron accumulation induces a biphasic change in the glutathione content of neuroblastoma cells.
Topics: Buthionine Sulfoximine; Cell Line, Tumor; Glutathione; Humans; Iron; Neuroblastoma; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Substantia Nigra | 2004 |
Reversible inhibition of mitochondrial complex I activity following chronic dopaminergic glutathione depletion in vitro: implications for Parkinson's disease.
Topics: Buthionine Sulfoximine; Cell Proliferation; Cells, Cultured; Dithiothreitol; Dopamine; Electron Transport Complex I; Glutamate-Cysteine Ligase; Glutathione; Humans; Mitochondria; Neurons; Nitric Oxide; Oxygen; Parkinson Disease; Peroxynitrous Acid; S-Nitrosothiols | 2006 |
Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies.
Topics: Animals; Antineoplastic Agents; Brain; Buthionine Sulfoximine; Cells, Cultured; Computer Simulation; Curcumin; Dopamine; Glutathione; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Mitochondria; Models, Theoretical; Neurons; Neuroprotective Agents; Oxidative Stress; Parkinson Disease; Rats; Systems Biology | 2008 |
Glutathione is involved in the granular storage of dopamine in rat PC 12 pheochromocytoma cells: implications for the pathogenesis of Parkinson's disease.
Topics: alpha-Methyltyrosine; Animals; Buthionine Sulfoximine; Cytoplasmic Granules; Dopamine; Glutathione; Methyltyrosines; Parkinson Disease; PC12 Cells; Rats; Reserpine | 1996 |
Glutathione depletion in rat brain does not cause nigrostriatal pathway degeneration.
Topics: Animals; Buthionine Sulfoximine; Corpus Striatum; Glutathione; Male; Nerve Degeneration; Neural Pathways; Parkinson Disease; Rats; Rats, Wistar; Substantia Nigra | 1997 |
Mitochondrial impairment as an early event in the process of apoptosis induced by glutathione depletion in neuronal cells: relevance to Parkinson's disease.
Topics: Animals; Apoptosis; Buthionine Sulfoximine; Cell Line; Electron Transport; Enzyme Inhibitors; Glutamate-Cysteine Ligase; Glutathione; Mice; Mitochondria; Neurons; Oxidation-Reduction; Oxidative Stress; Parkinson Disease; Time Factors; Tumor Cells, Cultured | 1998 |
Altered glial function causes neuronal death and increases neuronal susceptibility to 1-methyl-4-phenylpyridinium- and 6-hydroxydopamine-induced toxicity in astrocytic/ventral mesencephalic co-cultures.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; Astrocytes; Buthionine Sulfoximine; Cells, Cultured; Coculture Techniques; Dizocilpine Maleate; Dopamine; Electron Transport Complex I; Excitatory Amino Acid Antagonists; Glutathione; Lipopolysaccharides; Mesencephalon; NADH, NADPH Oxidoreductases; Oxidopamine; Parkinson Disease; Rats; Rats, Sprague-Dawley | 1999 |
Preferential resistance of dopaminergic neurons to the toxicity of glutathione depletion is independent of cellular glutathione peroxidase and is mediated by tetrahydrobiopterin.
Topics: Animals; Antioxidants; Biopterins; Buthionine Sulfoximine; Cell Survival; Dopamine; Enzyme Inhibitors; Female; Glutathione; Glutathione Peroxidase; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurons; Parkinson Disease; Pregnancy; Pteridines; Pterins; Pyrazoles; Rats; Rats, Sprague-Dawley; tert-Butylhydroperoxide | 2000 |
The effects of ascorbic acid on dopamine-induced death of PC12 cells are dependent on exposure kinetics.
Topics: Animals; Ascorbic Acid; Buthionine Sulfoximine; Dopamine; Dose-Response Relationship, Drug; Drug Interactions; Glutathione; Nerve Degeneration; Neuroprotective Agents; Neurotoxins; Oxidative Stress; Oxidopamine; Parkinson Disease; PC12 Cells; Pharmacokinetics; Rats | 2000 |
Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson's disease.
Topics: Alkaloids; Aminoquinolines; Animals; Antioxidants; Apoptosis; Ascorbic Acid; Buthionine Sulfoximine; Carbazoles; Cell Division; Cells, Cultured; Cyclic GMP-Dependent Protein Kinases; Dopamine; Enzyme Inhibitors; Free Radicals; Glutathione; Glutathione Synthase; Guanylate Cyclase; Homeostasis; Hydrazines; Indoles; Mesencephalon; Methylene Blue; Nerve Tissue Proteins; Neurons; Nitric Oxide; Nitric Oxide Donors; Nitrogen Oxides; Nucleic Acid Synthesis Inhibitors; Parkinson Disease; Penicillamine; Protein Synthesis Inhibitors; Rats; Rats, Sprague-Dawley; Tyrosine 3-Monooxygenase | 2001 |
Glutathione depletion in nigrostriatal slice cultures: GABA loss, dopamine resistance and protection by the tetrahydrobiopterin precursor sepiapterin.
Topics: Animals; Animals, Newborn; Biopterins; Buthionine Sulfoximine; Coculture Techniques; Dopamine; Enzyme Inhibitors; gamma-Aminobutyric Acid; Glutathione; Homovanillic Acid; Hypoxanthines; Neostriatum; Organ Culture Techniques; Oxidative Stress; Parkinson Disease; Pteridines; Pterins; Rats; Substantia Nigra; Tyrosine 3-Monooxygenase | 2002 |